TECENTRIQ

This brand name is authorized in Austria, Australia, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Turkey, United Kingdom, United States

Active ingredients

The drug TECENTRIQ contains one active pharmaceutical ingredient (API):

1 Atezolizumab UNII 52CMI0WC3Y - ATEZOLIZUMAB

Atezolizumab is an Fc-engineered, humanised immunoglobulin G1 (IgG1) monoclonal antibody that directly binds to PD-L1 and provides a dual blockade of the PD-1 and B7.1 receptors, releasing PD-L1/PD-1 mediated inhibition of the immune response, including reactivating the antitumour immune response without inducing antibody-dependent cellular cytotoxicity. Read about Atezolizumab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
TECENTRIQ Concentrate for solution for infusion	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01FF05	Atezolizumab	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FF PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors
Discover more medicines within L01FF05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 11277M, 11284X, 11297N, 11309F, 11792P, 11801D, 11802E, 11807K, 11926Q, 11927R, 11928T, 11929W, 11930X, 11931Y, 11940K, 11957H, 12076N, 12078Q, 12097Q, 12098R, 12155R, 12159Y, 12163E, 12164F, 12167J, 12168K, 12171N, 12174R
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 529218020027002, 529219110026507
Country: CA	Health Products and Food Branch	Identifier(s): 02462990, 02492393
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): 125-MBE-0318, 203-MBE-0621
Country: EE	Ravimiamet	Identifier(s): 1753747, 1800885
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 1171220001, 1171220001IP, 1171220002
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 494639, 533425
Country: FR	Base de données publique des médicaments	Identifier(s): 60345905, 64422886
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 348083, 376167, 392553, 392555
Country: HK	Department of Health Drug Office	Identifier(s): 65567, 66341, 66613
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 8103, 8720
Country: IT	Agenzia del Farmaco	Identifier(s): 045590015, 045590027
Country: JP	医薬品医療機器総合機構	Identifier(s): 4291441A1024, 4291441A2020
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1084155, 1088428
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 148482, 199230
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 18470, 20388
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100395410, 100423803
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W64295001, W66772001
Country: SG	Health Sciences Authority	Identifier(s): 15425P
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699505763323, 8699505763460
Country: US	FDA, National Drug Code	Identifier(s): 50242-917, 50242-918